Asset Details
Do you wish to reserve the book?
Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial
Do you wish to request the book?
Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial
2016
Overview
Background
Body surface area (BSA)-based prednisolone dosing for childhood nephrotic syndrome (NS) leads to higher cumulative prednisolone doses than body weight (BW)-based dosing. The clinical effects of this higher dosage have not been evaluated in prospective studies.
Methods
This parallel-group open-label randomized clinical trial enrolled 100 children with idiopathic NS, to receive BW-based (
n
= 50) or BSA-based (
n
= 50) prednisolone dosing by block randomization in a 1:1 ratio. The time taken for remission, relapse rate per 6 months, and adverse effects of steroids were analyzed in both groups.
Results
There was no significant difference in the time taken for remission in the BW group versus the BSA group (median (IQR) 7 (4.5–9) versus 5.5 (4–8) days;
p
= 0.082); similar results were observed on subgroup analysis in new-onset and infrequently-relapsing NS (IFRNS). The cumulative prednisolone dosage during the enrolment episode was higher in the BSA group. The incidence of hypertension was higher (
p
= 0.048) in the BSA group on per-protocol analysis. The relapse rates in the two groups per 6 months on follow-up were comparable.
Conclusions
Clinical outcomes with BW-based dosing are equivalent to BSA dosing-related outcomes, although cumulative prednisolone doses are lower in the former. The practice of BW-based calculations for prescribing prednisolone in NS is a reasonable approach.
Publisher
Springer Berlin Heidelberg,Springer,Springer Nature B.V
Subject
/ Child
/ Female
/ Glucocorticoids - administration & dosage
/ Glucocorticoids - adverse effects
/ Humans
/ India
/ Infant
/ Male
/ Medicine
/ Nephrotic Syndrome - diagnosis
/ Nephrotic Syndrome - drug therapy
/ Prednisolone - administration & dosage
/ Prednisolone - adverse effects
/ Steroids
/ Urology
